GeoVax CEO Named to 'PharmaVoice 100' for 2010

ATLANTA, Aug. 2 /PRNewswire-FirstCall/ -- Dr. Robert McNally, CEO of GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has been named to the "PharmaVoice 100" for 2010 by readers of PharmaVoice magazine.  This honor is bestowed on those whom the magazine's readers judge as the 100 most inspiring people in the life sciences industry.  A profile of Dr. McNally appears in the July/August issue of PharmaVoice.

According to the profile, "Thanks to Dr. McNally's hard work and persistence, GeoVax Labs, which creates, develops and tests innovative HIV/AIDS vaccines, is starting to make real progress."

The profile additionally notes, "A motivating leader, Dr. McNally's willingness to be actively involved as a hands-on leader has spurred his team to achieve important milestones for the company."

Commenting on the honor, Dr. McNally stated, "Recognition by PharmaVoice of our Company's activities is a great way to raise our profile as a company poised to prove the potential life saving benefit of our preventative and therapeutic HIV/AIDS vaccines. The attention garnered by this coverage may attract new interest in our vaccines and help us advance our goals of creating a commercially available product."  

To read the complete PharmaVoice profile of Dr. McNally, please visit this link: http://www.pharmavoice.com/content/digital/welcome.html

Dr. McNally's profile can be viewed on page 31.

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

SOURCE GeoVax Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED